FDA to review Theravance ’ s application for once-daily COPD med

The FDA has accepted Theravance Biopharma‘s (NSDQ:TBPH)  marketing application for revefenacin, an inhaled long-acting muscarinic antagonist designed to treat chronic obstructive pulmonary disease. The FDA is slated to make a decision about the once-daily treatment by Nov. 13. Get the full story at our sister site, Drug Delivery Business News. The post FDA to review Theravance’s application for once-daily COPD med appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Mylan Theravance Source Type: news